

This press release contains forward-looking statements and you are cautioned not to place undue reliance on any forward-looking statements contained herein. We can give no assurance that these forward-looking statements will prove to have been correct. Expectations reflected in these forward-looking statements are subject to change and we undertake no obligation and do not intend to update or revise any forward-looking statements herein.



中國抗體製藥有限公司

SinoMab BioScience Limited

(Stock Code : 3681.HK)

SinoMab BioScience Was Over-Subscribed by approximately 11.87 Times for HKPO

Final Offer Price Determined at HK\$7.60 per Offer Share

Net Proceeds of approximately HK\$1,286.44 million from Global Offering

[11 November 2019, Hong Kong] **SinoMab BioScience Limited** (“**SinoMab BioScience**” or the “**Company**”, together with its subsidiaries, the “**Group**”; stock code: **3681.HK**), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, today announced its offer price and the allotment results of its Global Offering. The total number of Offer Shares under the Global Offering amounts to 182,129,400 Shares, with the final offer price determined at HK\$7.60 per Offer Share. The net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and commissions and expenses payable by the Company in connection with the Global Offering and assuming the full payment of the discretionary incentive fee and that the Over-allotment Option is not exercised, are estimated to be approximately HK\$1,286.44 million.

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been significantly over-subscribed. The total number of valid applications amounts to approximately 12.87

times of the total number of Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering. The Offer Shares initially offered under the International Offering were also over-subscribed by approximately 1.38 times. The final numbers of Hong Kong Offer Shares and International Offer Shares are 18,213,000 and 163,916,400 Offer Shares respectively, representing respectively approximately 10.00% and 90.00% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option.

Pursuant to the cornerstone investment agreements that SinoMab BioScience entered into with the cornerstone investors, Yunnan Baiyao Group Co. Ltd and Reach Software (Hongkong) Limited have respectively subscribed for 51,599,400 Shares and 10,319,700 Shares, in all totaling 61,919,100 Shares, representing approximately 34.00% of the Offer Shares under the Global Offering assuming that the Over-allotment Option is not exercised.

The net proceeds will be used mainly for the R&D and commercialization of the Company's drug candidates, including funding clinical trials for its Core Product, SM03, further expanding its R&D team, building its commercialization team and discovering and developing new drug candidates not currently in its pipeline. The Company will also use the net proceeds for the construction of its Suzhou production base primarily for the commercial scale production of SM03, including the purchase of the laboratory and manufacturing equipment and land from the Suzhou Dushu Lake Higher Education Town.

China International Capital Corporation Hong Kong Securities Limited ("CICC") and Orient Capital (Hong Kong) Limited are the Joint Sponsors; CICC and Orient Securities (Hong Kong) Limited are the Joint Global Coordinators, the Joint Bookrunners and the Joint Lead Managers; China Everbright Securities (HK) Limited, Guotai Junan Securities (Hong Kong) Limited, CMB International Capital Limited, Haitong International Securities Company Limited, Fosun Hani Securities Limited and Victory Securities Company Limited are the Joint Bookrunners and the Joint Lead Managers.

Assuming that the Global Offering becomes unconditional in all aspects at or before 8:00 a.m. (Hong Kong time) on Tuesday, November 12, 2019, dealings in the Shares of the Company on the Main Board of The Stock Exchange of Hong Kong Limited are expected to commence at 9:00 a.m. (Hong Kong time) on Tuesday, November 12 2019 under the stock code of 3681, in board lots of 300 Shares each.

– End –

About SinoMab BioScience Limited

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: **3681.HK**) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.

This press release is issued by Porda Havas International Finance Communications Group for and on behalf of **SinoMab BioScience Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Ms. Angela Shi	+852 3150 6778	angela.shi@pordahavas.com
Ms. Nicola Lung	+852 3150 6791	nicola.lung@pordahavas.com
Ms. Sarah Liang	+852 3150 6765	sarah.liang@pordahavas.com
Ms. Aimee Zhong	+852 3150 6769	aimee.zhong@pordahavas.com